Leading a new era in precision diagnosis of neurocognitive disorders

ViewMind's AI-powered comprehensive neurocognitive health assessments provide the highest sensitivity and specificity by analyzing eye movement patterns
The eyes are the clearest pathway into the brain. By tracking eye movements, ViewMind is able to access the purest form of brain health data to diagnose and monitor Alzheimer’s disease and other neurocognitive disorders

Nearly 1 in 9

(over 1 billion individuals) suffer from neurological disorders
Source: WHO

1 in 9

people 65 and older have Alzheimer's disease
Source: Alzheimer's Association

78 million people

are expected to be affected by Alzheimer’s by 2030 globally, an increase of 40%
Source: WHO
Ojaswi Rana
Best Practices Research Analyst
 - 
Frost& Sullivan
"ViewMind's technology applies to a range of neurocognitive conditions, an exceptional and unique value proposition.
ViewMind has exceptional growth potential, with medical centers, clinics, and elderly care centers rapidly adopting its proprietary technology. 
The company’s offering spans the diagnostic continuum, from early stage to disease progression, monitoring, response, and treatment."

New possibilities for a more accurate diagnosis of Alzheimer’s and other neurocognitive disorders

Current neurocognitive pen and paper assessments lack the precision to detect minor changes in cognition and to accurately monitor them over time. Diagnostic procedures such as imaging and lumbar punctures are expensive and invasive. ViewMind can make neurodegenerative disease diagnosis accessible to more patients, earlier than ever.

PureSense™ — precision brain health technology

AI-powered model of neurocognitive performance

ViewMind's AI algorithms automatically model a person’s neurocognitive performance and brain functions, based on eye movement patterns in response to visual stimuli displayed in a VR headset.
Evaluation
A standardized assessment is conducted with the help of a medical-grade VR headset to track eye movements in response to specific stimuli
Data analysis
AI algorithms collect and analyze up to 100,000 data points in the ViewMind cloud to identify abnormalities in eye movement patterns
Diagnostic report
ViewMind generates a presumptive diagnostic report

ViewMind Leadership Team

Accomplished researchers in the fields of neuroscience, neurology and AI, and executives with medtech industry expertise
READ MORE ABOUT VIEWMIND
Mark Edwards
CEO
Experienced entrepreneur, CEO, founder, board member and builder of market leaders in both private and public companies in the software, AI, hardware and services industries.
Gerardo Fernandez PhD
CSO
18 years of experience researching eye movement patterns, neurology, and artificial intelligence.
Matias Shulz
COO
Experienced entrepreneur, founder and medtech executive.
David Orozco M.D.
Chief Medical Officer
Senior medical doctor practicing in the field of psychiatry.
Mario Parra, M.D., PhD
Neuroscientific Officer
Specialist in the field of Alzheimer's disease and related impairments.
Ariel Arelovich PhD
CTO
Full-stack software development leader and eye-tracking specialist.